Amgen Inc. (AMGN) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Amgen Inc.

    NASDAQ: AMGN · Real-Time Price · USD
    283.64
    3.54 (1.26%)
    At close: Sep 05, 2025, 3:59 PM
    283.19
    -0.16%
    After-hours: Sep 05, 2025, 07:16 PM EDT

    Amgen Revenue Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
    Aranesp Revenue 359M 340M 308M 337M 348M 349M 319M 323M 365M 355M 287M 358M 357M 358M 575M 396M 367M 355M 384M 387M 422M 316M 452M 436M 414M 477M 472M 454M
    Aranesp Revenue Growth +5.59% +10.39% -8.61% -3.16% -0.29% +9.40% -1.24% -11.51% +2.82% +23.69% -19.83% +0.28% -0.28% -37.74% +45.20% +7.90% +3.38% -7.55% -0.78% -8.29% +33.54% -30.09% +3.67% +5.31% -13.21% +1.06% +3.96% n/a
    BLINCYTO Revenue 384M 370M 381M 327M 264M 244M 1.01B 1.03B 1.07B 579M 348M 1.11B 1.05B 862M 362M 1.29B 1.14B 924M 1.32B 1.25B 1.15B n/a 1.37B 1.36B 1.15B 1.29B 1.3B 1.1B
    BLINCYTO Revenue Growth +3.78% -2.89% +16.51% +23.86% +8.20% -75.96% -1.93% -3.09% +84.46% +66.38% -68.54% +5.23% +21.93% +138.12% -71.92% +12.67% +23.81% -30.26% +6.34% +8.07% n/a n/a +0.22% +18.42% -10.91% -0.77% +17.83% n/a
    ENBREL Revenue 604M 510M 1.01B 825M 909M 567M 350M 307M 281M 254M 1.1B 318M 317M 287M 1.11B 293M 280M 251M 260M 253M 280M n/a 266M 267M 245M 1.06B 1.07B 949M
    ENBREL Revenue Growth +18.43% -49.75% +23.03% -9.24% +60.32% +62.00% +14.01% +9.25% +10.63% -76.87% +245.28% +0.32% +10.45% -74.10% +278.16% +4.64% +11.55% -3.46% +2.77% -9.64% n/a n/a -0.37% +8.98% -76.97% -0.84% +13.07% n/a
    EVENITY Revenue 518M 442M 431M 399M 391M 342M 386M 349M 346M 358M 325M 288M 284M 266M 284M 609M 534M 476M 538M 561M 479M n/a 1.24B 1.14B 960M 532M 610M 494M
    EVENITY Revenue Growth +17.19% +2.55% +8.02% +2.05% +14.33% -11.40% +10.60% +0.87% -3.35% +10.15% +12.85% +1.41% +6.77% -6.34% -53.37% +14.04% +12.18% -11.52% -4.10% +17.12% n/a n/a +8.41% +18.96% +80.45% -12.79% +23.48% n/a
    KRYSTEXXA Revenue 349M 236M 346M 310M 294M 235M 629M 419M 310M 362M 469M 627M 594M 451M 630M 1.73B 1.72B 1.59B 1.66B 1.57B 1.59B n/a 630M 698M 592M 433M 452M 445M
    KRYSTEXXA Revenue Growth +47.88% -31.79% +11.61% +5.44% +25.11% -62.64% +50.12% +35.16% -14.36% -22.81% -25.20% +5.56% +31.71% -28.41% -63.50% +0.64% +7.73% -3.81% +5.15% -0.82% n/a n/a -9.74% +17.91% +36.72% -4.20% +1.57% n/a
    Kyprolis Revenue 378M 324M 372M 378M 377M 376M 200M 567M 600M 392M 616M 1.63B 1.59B 1.48B 818M 386M 814M 758M 701M 659M 654M n/a 476M 499M 471M 394M 380M n/a
    Kyprolis Revenue Growth +16.67% -12.90% -1.59% +0.27% +0.27% +88.00% -64.73% -5.50% +53.06% -36.36% -62.14% +2.46% +7.59% +80.44% +111.92% -52.58% +7.39% +8.13% +6.37% +0.76% n/a n/a -4.61% +5.94% +19.54% +3.68% n/a n/a
    Nplate Revenue 369M 313M 337M 456M 346M 317M 363M 1.64B 1.73B 1.7B 879M 415M 313M 507M 873M 803M 286M 286M 205M 200M 229M n/a 274M 297M 271M n/a n/a n/a
    Nplate Revenue Growth +17.89% -7.12% -26.10% +31.79% +9.15% -12.67% -77.83% -5.43% +2.12% +92.83% +111.81% +32.59% -38.26% -41.92% +8.72% +180.77% 0.00% +39.51% +2.50% -12.66% n/a n/a -7.74% +9.59% n/a n/a n/a n/a
    Otezla Revenue 618M 437M 624M 564M 544M 394M 1.11B 355M 303M 259M 992M 862M 922M 852M 273M 272M 488M 468M 481M 435M 481M n/a n/a n/a n/a n/a n/a n/a
    Otezla Revenue Growth +41.42% -29.97% +10.64% +3.68% +38.07% -64.41% +211.83% +17.16% +16.99% -73.89% +15.08% -6.51% +8.22% +212.09% +0.37% -44.26% +4.27% -2.70% +10.57% -9.56% n/a n/a n/a n/a n/a n/a n/a n/a
    Other Products Revenue 1.69B 1.65B 4.27B 1.36B 1.33B 1.37B 417M 986M 1.03B 927M 333M 309M 325M 329M 545M 517M 412M 309M 319M 298M 267M n/a n/a n/a n/a n/a n/a n/a
    Other Products Revenue Growth +2.61% -61.40% +213.06% +2.79% -3.42% +229.26% -57.71% -4.09% +10.90% +178.38% +7.77% -4.92% -1.22% -39.63% +5.42% +25.49% +33.33% -3.13% +7.05% +11.61% n/a n/a n/a n/a n/a n/a n/a n/a
    Product and Service, Other Revenue 408M 276M 1.05B 352M 347M 329M 527M 406M 424M 388M 484M 495M 533M 502M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Product and Service, Other Revenue Growth +47.83% -73.61% +197.16% +1.44% +5.47% -37.57% +29.80% -4.25% +9.28% -19.83% -2.22% -7.13% +6.18% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Prolia Revenue 1.12B 1.1B 1.17B 1.04B 1.17B 999M n/a 519M 530M 536M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Prolia Revenue Growth +2.09% -5.67% +11.48% -10.30% +16.62% n/a n/a -2.08% -1.12% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Repatha (evolocumab) Revenue 696M 656M 606M 567M 532M 517M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Repatha (evolocumab) Revenue Growth +6.10% +8.25% +6.88% +6.58% +2.90% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    TEPEZZA Revenue 505M 381M 460M 488M 479M 424M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    TEPEZZA Revenue Growth +32.55% -17.17% -5.74% +1.88% +12.97% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    TEZSPIRE Revenue 342M 285M 296M 269M 234M 173M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    TEZSPIRE Revenue Growth +20.00% -3.72% +10.04% +14.96% +35.26% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Vectibix Revenue 305M 267M 246M 282M 270M 247M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Vectibix Revenue Growth +14.23% +8.54% -12.77% +4.44% +9.31% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    XGEVA Revenue 532M 566M 561M 541M 562M 561M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    XGEVA Revenue Growth -6.01% +0.89% +3.70% -3.74% +0.18% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Revenue by Geography

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
    Non-Us Revenue 2.45B 2.21B 3.04B 2.17B 2.2B 2.15B 2.71B 1.86B 1.95B 1.87B 2.43B 1.77B 1.83B 1.69B 2.59B 1.76B 1.74B 1.69B 2.35B 1.49B 1.48B 1.61B 1.98B 1.43B 1.43B 1.29B 1.63B 1.25B 1.31B 1.2B
    Non-Us Revenue Growth +10.67% -27.34% +40.10% -1.32% +2.61% -20.82% +45.88% -4.62% +4.06% -22.94% +37.10% -3.49% +8.32% -34.70% +47.22% +1.26% +3.02% -28.04% +57.94% +0.41% -8.36% -18.31% +37.87% +0.14% +10.58% -20.60% +30.48% -4.73% +9.70% n/a
    United States Revenue 6.32B 5.66B 7.07B 5.98B 5.84B 4.97B 6.4B 4.69B 4.74B 3.98B 5.65B 4.47B 4.45B 4.04B 5.36B 4.56B 4.37B 3.9B 5.17B 4.62B 4.43B 4.28B 5.06B 4.03B 4.14B 3.99B 5.58B 4.26B 4.37B 4.15B
    United States Revenue Growth +11.69% -19.93% +18.26% +2.38% +17.43% -22.35% +36.52% -0.95% +19.14% -29.60% +26.42% +0.45% +10.13% -24.67% +17.57% +4.21% +12.07% -24.52% +11.97% +4.29% +3.48% -15.47% +25.64% -2.73% +3.78% -28.53% +31.08% -2.45% +5.31% n/a

    Operating Expense Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 1.69B 1.69B 1.88B 1.63B 1.78B 1.81B 2.27B 1.35B 1.29B 1.26B 1.57B 1.29B 1.33B 1.23B 1.43B 1.3B 1.38B 1.25B 1.77B 1.35B 1.29B 1.32B 1.51B 1.22B 1.26B 1.15B 1.56B 1.29B 1.35B 1.13B 1.43B 1.17B 1.21B 1.06B 1.32B 1.24B 1.29B 1.2B 1.42B 1.24B 1.16B 1.03B
    Selling, General, and Administrative Revenue Growth +0.24% -10.17% +15.57% -8.96% -1.27% -20.49% +68.07% +4.56% +2.86% -19.97% +22.14% -3.01% +8.06% -13.82% +9.20% -5.71% +10.37% -29.27% +31.72% +3.94% -1.60% -13.02% +23.71% -2.94% +9.19% -25.98% +20.57% -4.43% +20.05% -21.02% +21.97% -3.23% +13.63% -19.58% +6.35% -3.72% +7.40% -15.04% +13.83% +7.24% +13.06% n/a
    Research and Development Revenue 1.74B 1.49B 1.72B 1.45B 1.45B 1.34B 1.53B 1.08B 1.11B 1.06B 1.32B 1.11B 1.04B 959M 1.35B 1.42B 1.08B 967M 1.23B 1.06B 964M 952M 1.31B 1B 924M 879M 1.18B 926M 869M 760M 1.04B 877M 873M 769M 1.08B 990M 900M 872M 1.09B 1.12B 964M 894M
    Research and Development Revenue Growth +17.36% -13.81% +18.90% +0.21% +7.74% -12.45% +42.17% -3.05% +5.20% -20.09% +19.06% +7.03% +8.34% -28.86% -5.20% +31.42% +11.89% -21.32% +15.73% +10.17% +1.26% -27.44% +31.07% +8.33% +5.12% -25.63% +27.65% +6.56% +14.34% -27.13% +18.93% +0.46% +13.52% -28.66% +8.89% +10.00% +3.21% -20.22% -2.32% +16.08% +7.83% n/a

    Add to Watchlist